Literature DB >> 8911222

Effects of tryptophan depletion in drug-free adults with autistic disorder.

C J McDougle1, S T Naylor, D J Cohen, G K Aghajanian, G R Heninger, L H Price.   

Abstract

BACKGROUND: The primary objective of this study was to investigate the behavioral and biochemical responses to acute tryptophan depletion in drug-free adult patients with autistic disorder.
METHODS: Twenty drug-free adults with autistic disorder (16 men and 4 women) (mean [+/- SD] age, 30.5 +/- 8.5 years) underwent short-term tryptophan depletion in a double-blind, placebo-controlled, randomized crossover design. Patients received a 24-hour, low-tryptophan diet followed the next morning by an amino acid drink. Behavioral ratings were obtained on the morning of the amino acid drink (baseline) and 180, 300, and 420 minutes after the drink. Plasma free and total tryptophan levels were obtained at baseline and 5 hours after the drink. The active and sham testing sessions were separated by 7 days.
RESULTS: Eleven (65%) of the 17 patients who completed both test days showed a significant global worsening of behavioral symptoms with short-term tryptophan depletion, but none of the 17 patients showed any significant change in clinical status from baseline after sham depletion (P = .001). Tryptophan depletion led to a significant increase in behaviors such as whirling, flapping, pacing, banging and hitting self, rocking, and toe walking (P < .05). In addition, patients were significantly less calm and happy and more anxious. No significant change was observed in social relatedness or repetitive thoughts and behavior. Plasma total and free tryptophan levels were reduced 86% and 69%, respectively, 5 hours after the tryptophan-deficient amino acid drink. Patients who had a significant global exacerbation of symptoms had significantly higher baseline plasma total tryptophan levels (P < .001) and Autism Behavior Checklist scores (P = .005) than did patients who showed no significant change in symptoms after tryptophan depletion.
CONCLUSIONS: The results of this study are consistent with previous research that has implicated a dysregulation in serotonin function in some patients with autism. These data suggest that the short-term reduction of serotonin precursor availability may exacerbate some symptoms characteristic of autism in some patients. Continued investigation into the role of serotonin in the pathogenesis and treatment of autistic disorder is warranted.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8911222     DOI: 10.1001/archpsyc.1996.01830110029004

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  73 in total

Review 1.  Autism: current theories regarding its pathogenesis and implications for rational pharmacotherapy.

Authors:  J K Buitelaar; S H Willemsen-Swinkels
Journal:  Paediatr Drugs       Date:  2000 Jan-Feb       Impact factor: 3.022

2.  The 5-HT(2A) receptor and serotonin transporter in Asperger's disorder: A PET study with [¹¹C]MDL 100907 and [¹¹C]DASB.

Authors:  Ragy R Girgis; Mark Slifstein; Xiaoyan Xu; W Gordon Frankle; Evdokia Anagnostou; Stacey Wasserman; Lauren Pepa; Alexander Kolevzon; Anissa Abi-Dargham; Marc Laruelle; Eric Hollander
Journal:  Psychiatry Res       Date:  2011-11-12       Impact factor: 3.222

3.  Plasma amino acids profiles in children with autism: potential risk of nutritional deficiencies.

Authors:  Georgianne L Arnold; Susan L Hyman; Robert A Mooney; Russell S Kirby
Journal:  J Autism Dev Disord       Date:  2003-08

Review 4.  Immune dysfunction in autism: a pathway to treatment.

Authors:  Milo Careaga; Judy Van de Water; Paul Ashwood
Journal:  Neurotherapeutics       Date:  2010-07       Impact factor: 7.620

Review 5.  Emerging drugs for the treatment of symptoms associated with autism spectrum disorders.

Authors:  Logan K Wink; Martin H Plawecki; Craig A Erickson; Kimberly A Stigler; Christopher J McDougle
Journal:  Expert Opin Emerg Drugs       Date:  2010-09       Impact factor: 4.191

6.  Serotonin transporter gene polymorphisms and hyperserotonemia in autistic disorder.

Authors:  C Betancur; M Corbex; C Spielewoy; A Philippe; J L Laplanche; J M Launay; C Gillberg; M C Mouren-Siméoni; M Hamon; B Giros; M Nosten-Bertrand; M Leboyer
Journal:  Mol Psychiatry       Date:  2002       Impact factor: 15.992

Review 7.  Early pharmacological treatment of autism: a rationale for developmental treatment.

Authors:  Terrence C Bethea; Linmarie Sikich
Journal:  Biol Psychiatry       Date:  2007-02-15       Impact factor: 13.382

8.  The minicolumnopathy of autism: A link between migraine and gastrointestinal symptoms.

Authors:  Manuel F Casanova
Journal:  Med Hypotheses       Date:  2007-06-14       Impact factor: 1.538

Review 9.  The serotonin system in autism spectrum disorder: From biomarker to animal models.

Authors:  C L Muller; A M J Anacker; J Veenstra-VanderWeele
Journal:  Neuroscience       Date:  2015-11-11       Impact factor: 3.590

10.  Examination of association of genes in the serotonin system to autism.

Authors:  B M Anderson; N C Schnetz-Boutaud; J Bartlett; A M Wotawa; H H Wright; R K Abramson; M L Cuccaro; J R Gilbert; M A Pericak-Vance; J L Haines
Journal:  Neurogenetics       Date:  2009-01-28       Impact factor: 2.660

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.